<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00257933</url>
  </required_header>
  <id_info>
    <org_study_id>2005-9-4377</org_study_id>
    <nct_id>NCT00257933</nct_id>
  </id_info>
  <brief_title>Oral Prednisolone Dosing in Children Hospitalized With Asthma</brief_title>
  <official_title>Oral Prednisolone Dosing in Children Hospitalized With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study hopes to determine the appropriate oral steroid dose for treating children
      hospitalized with asthma exacerbations. Practice guidelines from different countries
      recommend a wide range of doses, and the doses used in actual practice vary widely. There is
      no data on what is the most appropriate dose of prednisone (or equivalent) in this situation.
      We will be looking at the dose recommended by the National Asthma Education and Prevention
      Program guidelines, which are published by the National Heart, Lung, and Blood Institute, as
      compared with a lower dose which is commonly used in practice. We hypothesize that the lower
      dose will be no worse than the higher dose as determined primarily by duration of
      hospitalization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Practice guidelines for the management of asthma in children universally recommend systemic
      corticosteroids for the treatment of moderate to severe asthma exacerbations. However, these
      guidelines vary widely with respect to dose, frequency, method of delivery, and duration of
      therapy. In actual practice, there is also considerable variation among clinicians in terms
      of corticosteroid dosing in children hospitalized with asthma exacerbations. At the
      Children's Hospital of Philadelphia (CHOP) the current standard is to use an initial dose of
      4.0 mg/kg/day (1.0 mg/kg every 6 hours to a maximum of 30 mg/dose) although many other
      pediatric hospitals use a 2.0 mg/kg/day dose (1.0 mg/kg every 12 hours to a maximum of 30
      mg/dose). Systematic reviews of the literature have called for a clinical trial to evaluate
      the effect of different doses of corticosteroids in treating pediatric asthma patients
      hospitalized with exacerbations.

      This study will use a randomized, double-blind, controlled trial design in order to compare
      the efficacy of two different steroid doses in resolving acute exacerbations of asthma in
      hospitalized children. Children being hospitalized for asthma exacerbations from the CHOP
      emergency department (ED) will be eligible for study enrollment. Those that meet enrollment
      criteria will be randomized to receive prednisolone either in the higher dose (1.0 mg/kg (max
      30 mg) every 6 hours), or the lower dose (1.0 mg/kg (max 30 mg) every 12 hours and placebo
      doses at 6 hour intervals in between) for the first 48 hours of hospitalization. Once 48
      hours has past, all patients still hospitalized will receive 1.0 mg/kg (max 30 mg) every 12
      hours for the duration of hospitalization. Approximately 156 patients with 78 in each arm of
      the study will be enrolled. This study should be completed in six to eight months. A
      non-inferiority study design will be used. The primary outcome will be duration of
      hospitalization, as determined by duration of time elapsed from first dose of prednisolone
      administered in the emergency department (ED) until the discharge dose of albuterol is
      administered. Secondary outcomes will include time elapsed from the time the admission order
      is written until the discharge order is written, time spent in each severity level of the
      asthma care pathway, degree and rate of improvement in forced expiratory volume in one second
      (FEV1), improvement in peak expiratory flows (PEF), improvement in asthma symptom scores, and
      rate of relapse after discharge.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time Measured From the Administration of the Loading Dose of Prednisolone (2mg/kg up to Max 60mg) in the Emergency Department (ED) Until the Home Dose of Albuterol is Administered</measure>
    <time_frame>Median time from loading dose to home dose of albuterol</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time Measured From the Writing of the Admission Order Until the Writing of the Discharge Order</measure>
    <time_frame>Mean time from writing admit order until discharge order</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Spent in Each Severity Level of the Asthma Care Pathway</measure>
    <time_frame>Time spent in each severity level of pathway</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Rate and Degree of Change in Forced Expiratory Volume (FEV1) and Peak Expiratory Flow (PEF) Between Treatment Groups</measure>
    <time_frame>Every 4 hours during hospitalization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in Clinical Asthma Symptom Scores During Hospitalization Between Treatment Groups</measure>
    <time_frame>Every 4 hours during hospitalization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Relapse Between Treatment Groups</measure>
    <time_frame>2 weeks after hospitalization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose prednisolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lower dose prednisolone alternating with placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone high dose</intervention_name>
    <description>4 mg/kg/day orally divided every 6 hours (maximum 30 mg per dose)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>High Dose Prednisolone</other_name>
    <other_name>Oral steriod</other_name>
    <other_name>corticosteriods</other_name>
    <other_name>asthma exacerbations</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone lower dose</intervention_name>
    <description>2 mg/kg/day orally divided q 12 (maximum 30mg/dose) alternating with placebo</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Low dose Prednisolone</other_name>
    <other_name>Oral prednisolone</other_name>
    <other_name>Oral steriod</other_name>
    <other_name>corticosteriods</other_name>
    <other_name>asthma exacerbations</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Physician-diagnosed asthma with at least two previous visits to ED or primary care
             provider for asthma care

          -  Clinical decision by ED attending physician to admit to Acute Care Unit (ACU) after
             standardized initial ED treatment

        Exclusion Criteria:

          -  Clinical decision to begin continuous intravenous beta-agonist infusion

          -  Clinical decision to begin intravenous methylprednisolone therapy

          -  Clinical decision to admit to the Pediatric Intensive Care Unit

          -  Other concurrent disease such as sickle cell disease, cystic fibrosis, or cardiac
             disease

          -  Any contraindication to corticosteroid administration

          -  Any systemic corticosteroid treatment within two weeks of presenting to the ED

          -  Potential subjects will be excluded if informed consent is not obtained
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph J Zorc, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2005</study_first_submitted>
  <study_first_submitted_qc>November 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2005</study_first_posted>
  <results_first_submitted>July 14, 2010</results_first_submitted>
  <results_first_submitted_qc>July 14, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 11, 2010</results_first_posted>
  <last_update_submitted>December 23, 2010</last_update_submitted>
  <last_update_submitted_qc>December 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2010</last_update_posted>
  <responsible_party>
    <name_title>Joseph J. Zorc, M.D.</name_title>
    <organization>The Children's Hospital of Philadelphia</organization>
  </responsible_party>
  <keyword>Corticosteroids</keyword>
  <keyword>Treatment</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High Dose Prednisolone</title>
          <description>High dose prednisolone: 1 mg/kg of oral prednisolone (maximum 30mg) every 6 hours</description>
        </group>
        <group group_id="P2">
          <title>Lower Dose Prednisolone</title>
          <description>Lower dose prednisolone: 1 mg/kg (maximum 30mg)of oral prednisolone every 12 hours alternating with placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High Dose Prednisolone</title>
          <description>High dose prednisolone: 1 mg/kg of oral prednisolone (maximum 30mg) every 6 hours</description>
        </group>
        <group group_id="B2">
          <title>Lower Dose Prednisolone</title>
          <description>Lower dose prednisolone: 1 mg/kg (maximum 30mg)of oral prednisolone every 12 hours alternating with placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="74"/>
            <count group_id="B2" value="78"/>
            <count group_id="B3" value="152"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.9" spread="4.4"/>
                    <measurement group_id="B2" value="7.0" spread="3.8"/>
                    <measurement group_id="B3" value="7.4" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time Measured From the Administration of the Loading Dose of Prednisolone (2mg/kg up to Max 60mg) in the Emergency Department (ED) Until the Home Dose of Albuterol is Administered</title>
        <time_frame>Median time from loading dose to home dose of albuterol</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Prednisolone</title>
            <description>High dose prednisolone: 1 mg/kg of oral prednisolone (maximum 30mg) every 6 hours</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose Prednisolone</title>
            <description>Lower dose prednisolone: 1 mg/kg (maximum 30mg)of oral prednisolone every 12 hours alternating with placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time Measured From the Administration of the Loading Dose of Prednisolone (2mg/kg up to Max 60mg) in the Emergency Department (ED) Until the Home Dose of Albuterol is Administered</title>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="26" upper_limit="71"/>
                    <measurement group_id="O2" value="33" lower_limit="25" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Measured From the Writing of the Admission Order Until the Writing of the Discharge Order</title>
        <time_frame>Mean time from writing admit order until discharge order</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Spent in Each Severity Level of the Asthma Care Pathway</title>
        <time_frame>Time spent in each severity level of pathway</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Rate and Degree of Change in Forced Expiratory Volume (FEV1) and Peak Expiratory Flow (PEF) Between Treatment Groups</title>
        <time_frame>Every 4 hours during hospitalization</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differences in Clinical Asthma Symptom Scores During Hospitalization Between Treatment Groups</title>
        <time_frame>Every 4 hours during hospitalization</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Relapse Between Treatment Groups</title>
        <time_frame>2 weeks after hospitalization</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>High Dose Prednisolone</title>
          <description>High dose prednisolone: 1 mg/kg of oral prednisolone (maximum 30mg) every 6 hours</description>
        </group>
        <group group_id="E2">
          <title>Lower Dose Prednisolone</title>
          <description>Lower dose prednisolone: 1 mg/kg (maximum 30mg)of oral prednisolone every 12 hours alternating with placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limited ability to measure pulmonary function in hospitalized children with asthma did not allow measurement of this outcome.
Some protocol violations occurred
Single center study</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Joseph Zorc, MD</name_or_title>
      <organization>The Children's Hospital of Philadelphia</organization>
      <phone>215-590-1944</phone>
      <email>zorc@email.chop.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

